Author: Sabina Paglialunga

  • Celerion announces expanded state-of-the-art ADME Suite in its Lincoln, Nebraska USA facility

    Celerion announces expanded state-of-the-art ADME Suite in its Lincoln, Nebraska USA Facility

    The state-of-the-art ADME Suite benefits from on-site bioanalytical services and Phase I clinical facilities to offer clients a one stop solution.

    (Lincoln, NE; May 17, 2012) – Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce that it has expanded its ADME (Absorption, Distribution, Metabolism and Excretion) Suite in Lincoln, Nebraska USA. Celerion has invested in new state-of-the-art equipment and laboratory space to perform on-site scintillation counting allowing for radioactivity recovery results to be delivered in real-time. This service ensures high total recovery of radioactive dose while providing for efficient clinical study conduct.

    The newly expanded ADME Suite adds to Celerion’s capabilities to manage all aspects of human radiolabeled ADME studies from synthesis and formulation of an appropriate radiolabeled drug through dosimetry assessment and clinical conduct to final isolation, identification and quantification of metabolites in the samples collected. Radiolabel dosage forms suitable for administration to humans can be readily prepared at Celerion’s purpose-built pharmacy clean room at the Lincoln facility. Considering that the Lincoln clinic can also conduct micro-radiotracer studies, Celerion is one of a few organizations globally capable of conducting specialized human ADME studies to regulatory standards.

    “The enhancement in our facility was driven by client needs, including a growing interest in conducting these critical studies earlier in a drug’s development. This is a response to regulatory guidances concerning knowledge of human metabolism and metabolites during safety assessment,” said Raymond Farmen, Vice President, Global Bioanalytical Services. “The on-site bioanalytical and Phase I clinical facilities in Lincoln offer seamless integration of services and data. For bioanalytical analyses, the ADME suite interfaces with Celerion’s global electronic laboratory notebook system thereby increasing data compliance.”

    About Celerion

    Celerion is the premier provider of innovative early stage clinical research solutions. From facilities strategically located around the world, advanced scientific and technological expertise is applied to clinical research (over 730 beds in Phases 0, I and IIa, NDA-enabling clinical pharmacology, ADME), clinical pharmacology sciences, bioanalytical services (discovery through late stage), and drug development services. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. For more information, visit www.celerion.com.

    Media Contact:

    Farzana Azam
    Celerion
    Executive Director, Global Marketing
    media.inquiries@celerion.com

  • Celerion and Ricerca Biosciences announces “The Biosimilars Alliance” to offer clients a more effective development path for biosimilars

    Celerion and Ricerca Biosciences announces “The Biosimilars Alliance” to offer clients a more effective development path for biosimilars

    Celerion and Ricerca Biosciences announces “The Biosimilars Alliance” to offer clients a more effective development path for biosimilars

    (Lincoln, NE; Feb 29, 2012) – Celerion, the premier provider of innovative early stage drug development solutions, and Ricerca Biosciences, a drug safety assessment expert in harnessing external preclinical innovation, announce the formation of “The Biosimilars Alliance”. The Biosimilars Alliance is focused on preclinical and early clinical assessment of biologics manufactured by a new supplier.

    The formation of The Biosimilars Alliance was driven by client demand for an integrated service solution for the development of biosimilar products. The market for biosimilars is forecast to grow from $2.4B in 2012 to $44B by 2020. While there has been an established pathway for the approval of biosimilar products in Europe for several years, the US FDA has only recently issued its guidances. The foundation now exists for development of newly sourced versions of some of the most effective treatments that have emerged from medical research in the last 20 years.

    The Biosimilars Alliance offers convenient access to all of the specialized services required to perform early assessment of the viability of a potential biosimilar product before beginning costly multi-center comparator studies in the target patient populations. These services include in vitro and in vivo pharmacological assessments of activity and toxicological and immunotoxicological studies to support CTAs and INDs. Importantly, The Biosimilars Alliance also provides access to bioanalytical assay development to enable pharmacokinetic (PK) and pharmacodynamic (PD) assessments in animal and human studies, PK/PD modeling, immunogenicity screening during clinical studies and the regulatory and integrated project management support to ensure timely results for strategic decision-making.

    “The announcement of The Biosimilars Alliance demonstrates Celerion’s ability to respond to client needs and offer effective solutions that leverage the knowledge base built up over the past 20 years of supporting biologic drug development,” said Susan Thornton PhD, President and CEO at Celerion. “The formation of The Biosimilars Alliance is consistent with Celerion’s goal of providing fully integrated services to get to go/no go decisions quickly.”

    “Ricerca Biosciences is well positioned in Europe, Asia and North America to enhance the success of The Biosimilars Alliance. Biosimilars are a rapidly growing segment of the market and we see increasing demand from our clients for safety and efficacy testing to assess viability,” said Ian Lennox, CEO of Ricerca. “The Biosimilars Alliance is an important step for Ricerca in supporting the future needs of our clients.”

    The Biosimilars Alliance will also work with other solution providers to offer the full scope of services required to bring biosimilar products to market.

    About Celerion
    Celerion is the premier provider of innovative early stage clinical research solutions. From facilities strategically located around the world, advanced scientific and technological expertise is applied to global clinical research (over 730 beds in Phases 0, I and IIa, NDA-enabling clinical pharmacology, ADME), clinical pharmacology sciences, global bioanalytical services (discovery through late stage), and drug development services. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. For more information, visit www.celerion.com.

    About Ricerca Biosciences
    Ricerca Biosciences, offers a comprehensive suite of discovery, preclinical and development services to support drug candidates from discovery through IND and NDA on a global scale. Capabilities include molecular through in vivo screening and profiling, medicinal chemistry, IND-enabling toxicology, API process chemistry and cGMP manufacturing of clinical and commercial API. At Ricerca, our scientific excellence and reliable, cost-effective strategies help accelerate your drug discovery programs via our U.S.-based facilities in Concord, Ohio, and Bothell, Washington, and our ISO 9001-certified facilities in Taipei, Taiwan, and Lyon, France. The Lyon and Concord facilities hold AAALAC certification. For more information, visit www.ricerca.com.

    Media Contact:

    Farzana Azam
    Celerion
    Senior Director, Global Marketing
    media.inquiries@celerion.com

  • Celerion First Early Stage Contract Research Organization to Adopt a Participant Verification System to Improve Participant Safety and Data Quality

    Celerion First Early Stage Contract Research Organization to Adopt a Participant Verification System to Improve Participant Safety and Data Quality

    Celerion First Early Stage Contract Research Organization to Adopt a Participant Verification System to Improve Participant Safety and Data Quality

    (Lincoln, NE; Feb 02, 2012) – Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce it has implemented VCT Verify™ from Verified Clinical Trials, to instantaneously ensure accurate participant identification and qualification for clinical research. Celerion is the first Early Stage Contract Research Organization (CRO) to partner with Verified Clinical Trials to set the standard for the industry to adopt.

    Celerion will more effectively screen and select higher quality study participants by using this tool to instantly identify ineligible candidates for enrollment.  The system searches a global clinical database registry to identify participants that are currently enrolled in other clinical studies. Clients benefit from improved participant selection and higher data integrity.

    Celerion chose to implement the VCT Verify™ product across all our global clinical facilities to solve the long recognized problem of inaccurate applications that compromise study success.  The system has been reviewed and applauded by numerous Institutional Review Boards (IRBs) and Verified Clinical Trials is safe harbor certified.

    “Celerion continues to apply rigorous standards to protect the safety of participants and enhance data integrity while supporting our commitment to our clients. This implementation sets a standard in the industry to continue to improve clinical research and more effectively bring new drugs to the market,” said Phil Bach, Vice President of Global Clinical Research at Celerion. “We are excited to partner with Verified Clinical Trials, the leader in this specialized field, to take a firm stance on ensuring the highest quality data and participants for our clients.”

    “Verified Clinical Trials offers a comprehensive and unique clinical research database registry to enhance the quality of both early and late stage studies globally. The system has been designed to streamline the clinical trial process and offers protection from various other potential liabilities,” said Mitchell Efros, MD FACS, CEO at Verified Clinical Trials. “We are pleased to be working with Celerion, the first CRO to implement this product, as they continue to demonstrate their leadership position in the industry.”

    About Celerion
    Celerion is the premier provider of innovative early stage clinical research solutions. From facilities strategically located around the world, advanced scientific and technological expertise is applied to global clinical research (over 730 beds in Phases 0, I and IIa, NDA-enabling clinical pharmacology, ADME), clinical pharmacology sciences, global bioanalytical services (discovery through late stage), and drug development services. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. For more information, visit www.celerion.com.

    About Verified Clinical Trials
    Verified Clinical Trials is a forward thinking company developed by experts active in the clinical research community to proactively improve research subject safety and data quality in clinical research trials.  Verified Clinical Trials defines itself as the world’s leader in the field of database registries in clinical trial research.  Verified Clinical Trials is the only clinical research database registry designed specifically to enhance the quality of both early and late phase trials and has the scalability to reach all sites nationally as well as on a global level.  Verified Clinical Trials offers numerous other value added services to the clinical research site, CRO, and Pharmaceutical Sponsor, that prove invaluable with regards to financial and legal issues and liabilities. For more information, visit www.verifiedclinicaltrials.com.

    Media Contact:

    Farzana Azam
    Senior Director, Global Marketing
    media.inquiries@celerion.com

     

  • Celerion scientist proud recipient of Scientific and Technological Achievement Award (STAA) from EPA

    Celerion scientist proud recipient of Scientific and Technological Achievement Award (STAA) from EPA

    Celerion scientist proud recipient of Scientific and Technological Achievement Award (STAA) from EPA.

    (Lincoln, NE; Jan 11, 2012) – Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce Don Graff, PharmD, has received the prestigious Scientific and Technological Achievement Award (STAA) from the United States Environmental Protection Agency (EPA). The award is based on the research Dr. Graff undertook while at the EPA, prior to joining the Clinical Pharmacology Sciences business at Celerion.

    The body of work submitted for the award examined the findings of epidemiological studies conducted in the US and around the world. These data show that various subsets of the population are at risk to suffer cardiopulmonary events, including death, following episodes of elevated particulate matter (PM) pollution in the air. This work addresses biological plausibility and demonstrates that various size fractions of PM may be responsible for the diverse health effects noted in previous studies.

    Dr. Graff earned a Doctor of Pharmacy degree and completed a residency in Pharmacy Practice at the University of Nebraska Medical Center. He continued his post-graduate training at the University of North Carolina-Chapel Hill where his research focused on treatment and pathophysiology of heart failure. Upon joining the EPA, his work continued in the cardiopulmonary arena through bench-top and clinical studies assessing the effects of air pollution particulate matter on human health. In his role at Celerion, Dr. Graff has applied his cardiopulmonary expertise to the design and analysis of unique clinical research studies.

    “We are extremely proud of Dr. Graff, and the work submitted to the EPA. This research is especially relevant as it aligns with Celerion’s key strategic focus in the respiratory therapeutic area and early cardiac services,” said Michelle Combs PhD, Vice President of Clinical Pharmacology Sciences at Celerion. “This award is representative of the depth and breadth of scientific expertise that Celerion’s scientists have and is reflected in the high quality work delivered to our clients.”

    Celerion has one of the most experienced Clinical Pharmacology Sciences team operating in six global locations in North America and Europe for over 40 years. The team produces more than 200 clinical study reports annually and has developed over 4000 protocols.

    The mission of the EPA is to protect human health and the environment, and air pollution is a significant area of focus for the National Health and Environmental Effects Research Laboratory (NHEERL) within the EPA’s Office of Research and Development. For over two decades scientists at NHEERL have been conducting clinical studies evaluating the effects of air pollutants in support of the Clean Air Act, leading to the implementation of ozone and PM health advisory systems commonly used throughout the US. In addition, these studies have brought about considerable improvements in air quality and air pollution-related health outcomes.

    About Celerion
    Celerion is the premier provider of innovative early stage clinical research solutions. From facilities strategically located around the world, advanced scientific and technological expertise is applied to clinical research (over 730 beds in Phases 0, I and IIa, NDA – enabling clinical pharmacology, ADME), clinical pharmacology sciences, bioanalytical services (discovery through late stage), and drug development services. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. For more information, visit www.celerion.com.

  • Celerion receives license enabling Investigational Medicinal Products (IMPs) to be imported directly to their GMP-licensed facility

    Celerion receives license enabling Investigational Medicinal Products (IMPs) to be imported directly to their GMP-licensed facility

    The addition of the Import license saves time, costs and initiates direct communication earlier with clients to expedite early stage clinical studies.

    (Lincoln, NE; Sep 07, 2011) – Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce that its clinical research operations in Belfast, Northern Ireland UK, have received authorization from their competent authority, the Medicines and Healthcare product Regulatory Agency (MHRA) to have importation of IMPs added to their manufacturing (MIA(IMP)) license. The addition to the license enables the elimination of a third party vendor to import IMPs on behalf of Celerion thereby saving time, cost and initiating direct communication with clients to expedite early stage clinical studies.

    The import license gives Celerion’s facility in Belfast the ability to import investigational products from outside the European Economic Area when manufacturing standards from the exporting country have been confirmed as equivalent to the standards required by European legislation.

    “The addition of the import license was based on client demand and continues to demonstrate the high quality work and experience at Celerion,” said Phil Bach, Vice President of Global Clinical Research at Celerion. “This import license underpins Celerion’s commitment to a global clinical strategy and reduces the lead time from study concept to first dosing. Clients also benefit from reduced costs by eliminating third party storage and transport prior to certification of the product.”

    This latest announcement continues to demonstrate Celerion’s commitment to delivering upon the evolving needs of our clients and exemplifies the Belfast team’s commitment to meeting and exceeding our clients’ expectations.

    About Celerion
    Celerion is the premier provider of innovative early stage clinical research solutions. From facilities strategically located around the world, advanced scientific and technological expertise is applied to clinical research (over 730 beds in Phases 0, I and IIa, NDA – enabling clinical pharmacology, ADME), clinical pharmacology sciences, bioanalytical services (discovery through late stage), and drug development services. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. For more information, visit www.celerion.com.

  • Celerion appoints Dr. Raymond Farmen as Vice President of Global Bioanalytical Services

    Celerion appoints Dr. Raymond Farmen as Vice President of Global Bioanalytical Services

    Celerion appoints Dr. Raymond Farmen as Vice President of Global Bioanalytical Services

    (Lincoln, NE; Jun 29, 2011) – Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce the appointment of Dr. Raymond Farmen as Vice President of Global Bioanalytical Services. Dr. Farmen will have responsibility for the company’s bioanalytical operations in Zurich, Switzerland and Lincoln, Nebraska USA.

    Dr. Farmen comes to Celerion with over 30 years of experience in the contract research organization (CRO) and pharmaceutical industries. Prior to joining Celerion, he held executive positions at PharmOptima, a CRO that specializes in ocular research services; Eurofins AvTech Laboratories, a CRO that specializes in small and large molecule bioanalytical chemistry as well as QC testing and analysis of finished drug products and pharmaceutical ingredients; and Camargo Pharmaceutical Services, a CRO that provides scientific and regulatory oversight during the drug development process. Dr. Farmen also held leadership positions in the bioanalytical sciences at MDS Pharma Services, Phoenix International Life Sciences, and Bristol-Myers Squibb.

    Dr. Farmen has in-depth knowledge of both large and small molecule bioanalysis, DMPK, regulatory strategies, and GLP/GMP regulations. He played a pivotal role at the Crystal City meetings which helped to shape the early regulatory landscape and guidelines for bioanalysis of pharmaceutical products.

    “We are very pleased to have Ray on the management team at Celerion,” said Susan Thornton, President and CEO of Celerion. “His in-depth knowledge of drug development, bioanalysis and regulatory strategy from both the client and CRO perspective will be a great asset to our organization.”

    Dr. Farmen earned his doctorate in pharmacology from Indiana University and did post-doctoral research in Biochemistry at the Upstate Medical Center in Syracuse, New York.

    About Celerion
    Celerion is the premier provider of innovative early stage clinical research solutions. From facilities strategically located around the world, advanced scientific and technological expertise is applied to clinical research (over 730 beds in Phases 0, I and IIa, NDA-enabling clinical pharmacology, ADME), clinical pharmacology sciences, bioanalytical services (discovery through late stage), and drug development services. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. For more information, visit www.celerion.com.

  • Celerion achieves major milestone of successfully analyzing over 25,000 platelet aggregation samples

    Celerion achieves major milestone of successfully analyzing over 25,000 platelet aggregation samples

    Celerion achieves major milestone of successfully analyzing over 25,000 platelet aggregation samples.

    Celerion’s unmatched experience in platelet aggregation benefits clients by producing higher quality data, reduced timelines and lower costs.

    (Lincoln, NE; Jun 21, 2011) – Celerion, the premier provider of innovative early stage drug development solutions, announces it has achieved a major milestone of generating over 25,000 platelet aggregation sample results. These samples were collected from over 1000 participants dosed in more than 20 studies. Platelet function assays are inherently variable, so this level of experience is critical to produce reliable and accurate platelet aggregation results.

    The FDA public health advisory, released in 2009, described the potential for reduced anti-blood clotting activity due to drug-drug interactions. This has led to an increased need for platelet aggregation studies to better evaluate the impact of drug-drug interactions on platelet function.

    To meet this industry need and client demand, Celerion made significant investments to implement intensive staff training and added cutting edge technology. The fully trained staff, in combination with state-of-the-art analyzers has produced unparalleled precision. Equally important, by deploying this technology, Celerion has been able to increase cohort size on studies requiring platelet aggregation, from eight to 40 participants, creating efficiency in the conduct of these studies.

    “Reaching this milestone is a testament to Celerion’s ability to respond to the evolving needs of early clinical research,” said Phil Bach, Vice President, Global Clinical Research. “Our experience has already benefited many clients in producing high quality data efficiently, to help them achieve their goal of getting products to market sooner.”

    About Celerion
    Celerion is the premier provider of innovative early stage clinical research solutions. From facilities strategically located around the world, advanced scientific and technological expertise is applied to clinical research (over 730 beds, Phases 0, I and IIa, NDA-enabling clinical pharmacology, ADME), clinical pharmacology sciences, bioanalytical services (discovery through late stage), and drug development services. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. For more information, visit www.celerion.com.

  • Celerion announces highly automated ECG analysis enabling data delivery within 37 days from first patient dosed

    Celerion announces highly automated ECG analysis enabling data delivery within 37 days from first patient dosed

    Celerion announces highly automated ECG Analysis enabling data delivery within 37 days from first patient dosed

    Clients benefit from faster access to higher quality data and cost savings in their drug development programs.

    (Lincoln, NE; Jun 20, 2011) – Celerion, the premier provider of innovative early stage drug development solutions, announces the successful completion of a 133 participant parallel design Thorough QT (TQT) study using the innovative Celerion Hybrid Phase I/ ECG Core Lab. The efficiencies developed in both clinical conduct and ECG analysis enabled Celerion to quickly collect and analyze over 9,000 ECG recordings, delivering the final dataset containing all data for the study to the sponsor company within 37 days from first patient dosed.

    “This study continues to demonstrate Celerion’s commitment to implement innovative technologies that enable fast access to high quality data and ultimately save costs for clients,” said Phil Bach, Vice President of Global Clinical Research at Celerion. “The Hybrid Phase I/ ECG Core Lab, when used for the execution of TQT studies and ECG assessment in Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) studies, enables our clients to deliver on their goal of getting products to market faster.”

    The Hybrid Phase I/ ECG Core lab provides highly automated ECG analysis for Celerion’s global Phase I clinical network that minimizes cardiologist review time and expense. This novel approach was built upon the knowledge gained from conducting more than 100 studies with intensive ECG monitoring including 36 TQT studies and fully integrates both the core lab and clinic functions. Extensive experience in early cardiac safety services allowed Celerion to carefully define where efficiencies could be realized when developing the Hybrid Phase I/ ECG Core Lab. Integration of the core lab and clinic minimizes the inefficiencies associated with separate management of the two functions.

    About Celerion

    Celerion is the premier provider of innovative early stage clinical research solutions. From facilities strategically located around the world, advanced scientific and technological expertise is applied to clinical research (over 730 beds in Phases 0, I and IIa, NDA-enabling clinical pharmacology, ADME), clinical pharmacology sciences, bioanalytical services (discovery through late stage), and drug development services. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. For more information, visit www.celerion.com.

  • Celerion receives ANVISA certification

    Celerion receives ANVISA certification

    Celerion receives ANVISA certification

    Brazilian Regulatory Agency Approves Celerion Facilities in both North America and Europe to Conduct Clinical Research and Bioanalytical Services.

    (Lincoln, NE; Jun 9, 2011) – Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce that its clinical research operations in Belfast, Northern Ireland UK, and its clinical research and bioanalytical services operations in Lincoln, Nebraska USA, have been certified by the Brazilian National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária – ANVISA).

    ANVISA provides regulatory approval for drugs and other products seeking to enter the large and growing Brazilian market. ANVISA-certified service providers are uniquely qualified to help clients clear a key hurdle to access one of the fastest-growing major pharmaceutical markets in the world.

    “The approval of ANVISA continues to demonstrate the high quality work done at Celerion.” said Susan Thornton, President and CEO. “By earning ANVISA certification to conduct early clinical studies and bioanalytical research for compounds destined for Brazil, Celerion is now able to better serve our clients’ growing needs in this high–growth, emerging market.”

    In addition to ANVISA certification, Celerion’s Belfast, facility has also been certified by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). The facility has received both Standard and Supplementary Accreditation from the MHRA, which certifies that the general standards for study participant safety and access to emergency medical response have been met. The MHRA accreditation attests to Celerion’s commitment to participant safety.

    About Celerion

    Celerion is the premier provider of innovative early stage clinical research solutions. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. From facilities strategically located around the world, advanced scientific and technological expertise is applied to clinical research (Phases 0, I and IIa, NDA-enabling clinical pharmacology, ADME), clinical pharmacology sciences, bioanalytical services (discovery through late stage), and drug development services. For more information, visit www.celerion.com.

  • Celerion awarded prestigious LEED® Green Building Certification

    Celerion awarded prestigious LEED® Green Building Certification

    Celerion Awarded Prestigious LEED® Green Building Certification

    Celerion is the first research clinic in the U.S. to be awarded LEED® Silver certification.

    (Lincoln, NE; May 26, 2011) – Celerion, a premier provider of innovative early stage drug development solutions, announced today that it has been awarded LEED® Silver established by the U.S. Green Building Council and verified by the Green Building Certification Institute (GBCI). LEED is the nation’s preeminent program for the design, construction and operation of high performance green buildings.

    Celerion is the leading provider of comprehensive early stage clinical research and bioanalytical services to the drug development community. The facility in Phoenix, Arizona is a state-of-the-art 300 bed, 104,947sf, early clinical research facility and is the Center of Excellence for early cardiac studies. Celerion was the first CRO to launch the Hybrid Phase I/ECG Core lab, which was developed in Phoenix, and launched to our global network of clinics.

    Celerion achieved certification under the LEED for Existing Buildings: Operation & Maintenance rating system for energy use, lighting, water and material use, as well as incorporating a variety of other sustainable strategies to make it the first research clinic of its type in the country to attain such an honor. By using less energy and water, LEED certified buildings save money for families, businesses and taxpayers; reduce greenhouse gas emissions; and contribute to a healthier environment for residents, workers and the larger community.

    “We are very pleased to receive this certification,” said Susan Thornton, President and CEO of Celerion. “The upgrades made to our state-of-the-art facility in the Phoenix metropolitan area serve as an example of Celerion’s commitment to creating a healthy work environment, reducing our environment footprint and delivering more efficiency for clients. We applaud the leadership and hard work of our project team and the willingness of third party vendors to volunteer their time to achieving these important goals.” A primary focus for the team was to aggressively pursue no/low cost alternatives to successfully meet the certification requirements.

    “Celerion’s LEED certification demonstrates tremendous green building leadership,” said Rick Fedrizzi, President, CEO & Founding Chair, U.S. Green Building Council. “The urgency of USGBC’s mission has challenged the industry to move faster and reach further than ever before, and Celerion serves as a prime example with just how much we can accomplish.” LEED certification of Celerion was based on a number of green sustainable practices, and design & construction features that positively impact the project itself and the broader community. Some of these practices and features include:

    • Metering faucets, and ultra-low flow shower heads and aerators that contributed to a 25% reduction in water use
    • Collection of 73% of the precipitation falling on the entire site and grounds to reuse for irrigation or evapotranspirates
    • Water efficient landscaping by using a micro-irrigation system and native, adaptive plants
    • 39% participation in the Alternative Transportation/Trip Reduction Program to offset conventional automobile commuting
    • 80% reuse and recycling of consumable waste and 100% reuse, recycling of durable goods
    • Building systems perform 20% better than the national average for optimizing energy efficiency

    Celerion

    Celerion is the premier provider of innovative early stage clinical research solutions. Formed through the acquisition of the early stage development operations of MDS Pharma Services, Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. From facilities strategically located around the world, advanced scientific and technological expertise is applied to clinical research (Phases 0, I and IIa, NDA-enabling clinical pharmacology, ADME), clinical pharmacology sciences, bioanalytical services (discovery through late stage), and drug development services. For more information, visit www.celerion.com.

    The U.S. Green Building Council

    The Washington, D.C. based U.S. Green Building Council is committed to a prosperous and sustainable future for our nation through cost-efficient and energy-saving green buildings.

    With a community comprising 80 local affiliates, more than 18,000 member companies and organizations, and more than 155,000 LEED professional Credential holders, USGBC is the driving force of an industry that is projected to contribute $554 billion to the U.S. gross domestic product from 2009-2013. USGBC leads an unlikely diverse constituency of builders and environmentalists, corporations and nonprofit organizations, elected officials and concerned citizens, and teachers and students.

    Buildings in the United States are responsible for 39% of CO2 emissions, 40% of energy consumption, 13% water consumption and 15% of GDP per year, making green building a source of significant economic and environmental opportunity. Greater building efficiency can meet 85% of future U.S. demand for energy, and a national commitment to green building has the potential to generate 2.5 million American jobs.

    LEED

    THE U.S. Green Building Council’s LEED green building certification system is the foremost program for the design, construction and operation of green buildings. Over 32,000 projects are currently participating in the commercial and institutional LEED rating systems, comprising over 9.5 billion square feet of construction space in all 50 states and 114 countries. For more information, visit www.usgbc.org.